Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Henrik, Maagensen"'
Autor:
Anne Cathrine Baun Thuesen, Rasmus Tanderup Jensen, Henrik Maagensen, Maja Refshauge Kristiansen, Henrik Toft Sørensen, Allan Vaag, Henning Beck-Nielsen, Oluf B. Pedersen, Niels Grarup, Jens Steen Nielsen, Jørgen Rungby, Anette Prior Gjesing, Heidi Storgaard, Tina Vilsbøll, Torben Hansen
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 35, Iss , Pp 100972- (2023)
Background: Functionally disruptive variants in the glucokinase gene (GCK) cause a form of mild non-progressive hyperglycemia, which does not require pharmacological treatment. A substantial proportion of patients with type 2 diabetes (T2D) carry GCK
Externí odkaz:
https://doaj.org/article/1696d215ff0246ea81cfebf50fdc833b
Publikováno v:
Current osteoporosis reportsPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance.
To describe recent advances in the understanding of how gut-derived hormones regulate bone homeostasis in humans with emphasis on pathophysiological and therapeutic perspectives in diabetes.The gut-derived incretin hormone glucose-dependent insulinot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d843543491c7a4621d70e87a0d4d4a6
https://pubmed.ncbi.nlm.nih.gov/36441432
https://pubmed.ncbi.nlm.nih.gov/36441432
Autor:
HENRIK MAAGENSEN, SOFIE HAEDERSDAL, JESPER KROGH, TORBEN HANSEN, FILIP K. KNOP, TINA VILSBØLL
Publikováno v:
Diabetes. 71
Mutations in hepatocyte nuclear factor 1-alpha (HNF1A) cause HNF1A-diabetes (or maturity-onset diabetes of the young type 3 (MODY3)) . Treatment of HNF1A-diabetes is primarily based on sulphonylureas (SU) and secondarily insulins, glucagon-like pepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5acb9816440b47b56fb867f257f6257
https://doi.org/10.2337/db22-182-or
https://doi.org/10.2337/db22-182-or
Autor:
Elisabeth Nielsen-Hannerup, Filip K. Knop, Tina Vilsbøll, Sofie Hædersdal, Henrik Maagensen, Gerrit van Hall, Asger Lund, Jens J. Holst
Publikováno v:
Diabetes
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) effectively lower plasma glucose (PG) concentration in patients with type 2 diabetes, but studies have suggested that circulating glucagon concentrations and endogenous glucose production (EGP) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aff035e14f977810a8bf0bf1699dc74
https://doi.org/10.2337/db20-0369
https://doi.org/10.2337/db20-0369
Autor:
Sofie Hædersdal, Asger Lund, Henrik Maagensen, Elisabeth Nielsen-Hannerup, Lærke S Gasbjerg, Mette M Rosenkilde, Julie L Forman, Gerrit van Hall, Jens J Holst, Filip K Knop, Tina Vilsbøll
Publikováno v:
European journal of endocrinology. 186(2)
Objective Type 2 diabetes (T2D) pathophysiology includes fasting and postprandial hyperglucagonemia, which has been linked to hyperglycemia via increased endogenous glucose production (EGP). We used a glucagon receptor antagonist (LY2409021) and stab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4b879d2fc99a5c76d14d7a3c9b55c2
https://pubmed.ncbi.nlm.nih.gov/34863038
https://pubmed.ncbi.nlm.nih.gov/34863038
Autor:
Tina Vilsbøll, Filip K. Knop, Jens J. Holst, Gerrit van Hall, Henrik Maagensen, Elisabeth Nielsen-Hannerup, Asger Lund, Sofie Hædersdal, Ada Admin
Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) effectively lower plasma glucose (PG) concentration in patients with type 2 diabetes, but studies suggest that circulating glucagon concentrations and endogenous glucose production (EGP) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2afd85fad437500735bda3100017bb
https://doi.org/10.2337/figshare.13010123
https://doi.org/10.2337/figshare.13010123
Publikováno v:
Psychiatry Research. 296:113670
Schizophrenia is associated with a lowered bone mineral density. The antidiabetic and body weight lowering glucagon-like peptide-1 receptor agonist liraglutide has shown to mitigate overweight and impaired glucose tolerance associated with olanzapine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878564ecf747e307f8988d4b6987bfc3
https://doi.org/10.1016/j.psychres.2020.113670
https://doi.org/10.1016/j.psychres.2020.113670
Autor:
Elisabeth Nielsen-Hannerup, Tina Vilsbøll, Jens J. Holst, Sofie Hædersdal, Henrik Maagensen, Asger Lund, Filip K. Knop
Publikováno v:
BASE-Bielefeld Academic Search Engine
Type 2 diabetes is characterized by absolute or relative hypoinsulinemia and hyperglucagonemia. Dipeptidyl peptidase 4 inhibitors (DPP-4i) augment insulin secretion and decrease glucagon secretion, but if glucagon is removed from the metabolic equati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fcb0b6f571f211758957be534f3c7a0
https://doi.org/10.2337/db18-274-lb
https://doi.org/10.2337/db18-274-lb
Autor:
Tina Vilsbøll, Asger Lund, Elisabeth Nielsen-Hannerup, Filip K. Knop, Jens J. Holst, Sofie Hædersdal, Henrik Maagensen
Publikováno v:
Diabetes. 67
Studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT2i) induce hyperglucagonemia, which might counteract its glucose-lowering ability in type 2 diabetes. In a randomized, placebo-controlled, double-dummy, double-blinded, cross-over st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb311e790bea65035b2e8288ef47fce3
https://doi.org/10.2337/db18-1942-p
https://doi.org/10.2337/db18-1942-p
Autor:
Lise Lotte Gluud, Tina Vilsbøll, Niklas Rye Jørgensen, Henrik Maagensen, Anders Ellekær Junker, Filip K. Knop
Publikováno v:
BASE-Bielefeld Academic Search Engine
Maagensen, H, Junker, A E, Jørgensen, N R, Gluud, L L, Knop, F K & Vilsbøll, T 2018, ' Bone Turnover Markers in Patients with Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes during Oral Glucose and Isoglycemic Intravenous Glucose ', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 5, pp. 2042-2049 . https://doi.org/10.1210/jc.2018-00176
Maagensen, H, Junker, A E, Jørgensen, N R, Gluud, L L, Knop, F K & Vilsbøll, T 2018, ' Bone Turnover Markers in Patients with Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes during Oral Glucose and Isoglycemic Intravenous Glucose ', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 5, pp. 2042-2049 . https://doi.org/10.1210/jc.2018-00176
Context: Nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes (T2D) and vice versa, and both conditions are associated with an increased risk of fractures and altered bone turnover. Although patients with NAFLD typically suffer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b93e302b2ef0aa28c9b3494bbd743a1f
https://pubmed.ncbi.nlm.nih.gov/29506157
https://pubmed.ncbi.nlm.nih.gov/29506157